Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies
Chiranjib Chakraborty, Ashish Ranjan Sharma, Manojit Bhattacharya, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 136

Showing 1-25 of 136 citing articles:

A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations
Chiranjib Chakraborty, Ashish Ranjan Sharma, Manojit Bhattacharya, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 117
SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic
Chiranjib Chakraborty, Manojit Bhattacharya, Kuldeep Dhama
Vaccines (2023) Vol. 11, Iss. 3, pp. 682-682
Open Access | Times Cited: 56
A Comprehensive Review of Drug Repurposing Strategies against Known Drug Targets of COVID-19
Ankita Khataniar, Upasana Pathak, Sanchaita Rajkhowa, et al.
COVID (2022) Vol. 2, Iss. 2, pp. 148-167
Open Access | Times Cited: 48
Spectrofluorimetric quantitative analysis of favipiravir, remdesivir and hydroxychloroquine in spiked human plasma
Sherif Ramzy, Ahmed H. Abdelazim, Ayman Osman Elsayed, et al.
Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy (2022) Vol. 281, pp. 121625-121625
Closed Access | Times Cited: 37
Artificial intelligence enabled ChatGPT and large language models in drug target discovery, drug discovery, and development
Chiranjib Chakraborty, Manojit Bhattacharya, Sang‐Soo Lee
Molecular Therapy — Nucleic Acids (2023) Vol. 33, pp. 866-868
Open Access | Times Cited: 32
Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trial
Francesco Di Pierro, Amjad Khan, Somia Iqtadar, et al.
Frontiers in Pharmacology (2023) Vol. 13
Open Access | Times Cited: 29
Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
Srijan Chatterjee, Manojit Bhattacharya, Kuldeep Dhama, et al.
Molecular Therapy — Nucleic Acids (2023) Vol. 32, pp. 263-266
Open Access | Times Cited: 25
Accurate and interpretable drug-drug interaction prediction enabled by knowledge subgraph learning
Yaqing Wang, Zaifei Yang, Quanming Yao
Communications Medicine (2024) Vol. 4, Iss. 1
Open Access | Times Cited: 8
Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance
Chiranjib Chakraborty, Manojit Bhattacharya, Ashish Ranjan Sharma
Current Opinion in Pharmacology (2021) Vol. 62, pp. 64-73
Open Access | Times Cited: 42
SARS-CoV-2 Omicron Spike shows strong binding affinity and favourable interaction landscape with the TLR4/MD2 compared to other variants
Chiranjib Chakraborty, Bidyut Mallick, Manojit Bhattacharya, et al.
Journal of Genetic Engineering and Biotechnology (2024) Vol. 22, Iss. 1, pp. 100347-100347
Open Access | Times Cited: 5
Current landscape of long COVID clinical trials
Manojit Bhattacharya, Srijan Chatterjee, Sanskriti Saxena, et al.
International Immunopharmacology (2024) Vol. 132, pp. 111930-111930
Closed Access | Times Cited: 4
Parents’Attitudes, Their Acceptance of the COVID-19 Vaccines for Children and the Contributing Factors in Najran, Saudi Arabia: A Cross-Sectional Survey
Abdullah Ibrahim Aedh
Vaccines (2022) Vol. 10, Iss. 8, pp. 1264-1264
Open Access | Times Cited: 25
Enhanced Nasal Deposition and Anti-Coronavirus Effect of Favipiravir-Loaded Mucoadhesive Chitosan–Alginate Nanoparticles
Khent Primo Alcantara, Nonthaneth Nalinratana, Nopporn Chutiwitoonchai, et al.
Pharmaceutics (2022) Vol. 14, Iss. 12, pp. 2680-2680
Open Access | Times Cited: 24
Quantitative analysis of two COVID-19 antiviral agents, favipiravir and remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation
Afnan S. Batubara, Ahmed H. Abdelazim, Ahmed A. Almrasy, et al.
BMC Chemistry (2023) Vol. 17, Iss. 1
Open Access | Times Cited: 13
Streptomyces griseiviridis sp. nov., A Novel “Modern Actinobacteria” isolated from Malaysia Mangrove Soil
Jodi Woan‐Fei Law, Loh Teng‐Hern Tan, Vengadesh Letchumanan, et al.
Progress In Microbes & Molecular Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 12
Drug repositioning: current scenario and future prospective for rewriting saga of drug development
Alok Dixit, Ajit Mishra, C. Singh, et al.
International Journal of Research in Medical Sciences (2024) Vol. 12, Iss. 4, pp. 1334-1343
Open Access | Times Cited: 3
Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing
Jason R. Burchett, Jordan Dailey, Sydney Ann Kee, et al.
Cells (2022) Vol. 11, Iss. 19, pp. 3031-3031
Open Access | Times Cited: 18
Tautomerism and Rotamerism of Favipiravir and Halogenated Analogues in Solution and in the Solid State
Angel H. Romero, Germán Fuentes, Leopoldo Suescun, et al.
The Journal of Organic Chemistry (2023) Vol. 88, Iss. 15, pp. 10735-10752
Closed Access | Times Cited: 10
Exploring the structural and molecular interaction landscape of nirmatrelvir and Mpro complex: The study might assist in designing more potent antivirals targeting SARS-CoV-2 and other viruses
Chiranjib Chakraborty, Manojit Bhattacharya, Abdulrahman Alshammari, et al.
Journal of Infection and Public Health (2023) Vol. 16, Iss. 12, pp. 1961-1970
Open Access | Times Cited: 10
The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation
Marika Watanabe, Kimikazu Yakushijin, Yohei Funakoshi, et al.
Vaccines (2022) Vol. 10, Iss. 2, pp. 158-158
Open Access | Times Cited: 17
Aprotinin—Drug against Respiratory Diseases
Alexandre V. Ivachtchenko, A. V. Ivashchenko, Dmitrii O. Shkil, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 11173-11173
Open Access | Times Cited: 9
Anakinra authorized to treat severe coronavirus disease 2019; Sepsis breakthrough or time to reflect?
Leland Shapiro, Sias Scherger, Carlos Franco‐Paredes, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 8
Green chemometric-assisted UV-spectrophotometric methods for the determination of favipiravir, cefixime and moxifloxacin hydrochloride as an effective therapeutic combination for COVID-19; application in pharmaceutical form and spiked human plasma
Eman A. Madbouly, Abdalla A. El‐Shanawani, Sobhy M. El-Adl, et al.
BMC Chemistry (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 2
Artificial intelligence for drug repurposing against infectious diseases
Anuradha Singh
Artificial Intelligence Chemistry (2024) Vol. 2, Iss. 2, pp. 100071-100071
Open Access | Times Cited: 2
SARS-CoV-2 replication and drug discovery
Farah Nazir, Arnaud John Kombe Kombe, Zunera Khalid, et al.
Molecular and Cellular Probes (2024) Vol. 77, pp. 101973-101973
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top